Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study

SIMPLE SUMMARY: Immune-checkpoint inhibitors have only been studied in clinical trials for second-line and now first-line malignant pleural mesothelioma. Sometimes, results found in clinical trials do not translate to real-life settings. We aim to study second-line and onward nivolumab in malignant...

Descripción completa

Detalles Bibliográficos
Autores principales: Assié, Jean-Baptiste, Crépin, Florian, Grolleau, Emmanuel, Canellas, Anthony, Geier, Margaux, Grébert-Manuardi, Aude, Akkache, Nabila, Renault, Aldo, Hauss, Pierre-Alexandre, Sabatini, Marielle, Bonnefoy, Valentine, Cortot, Alexis, Wislez, Marie, Gauvain, Clément, Chouaïd, Christos, Scherpereel, Arnaud, Monnet, Isabelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946798/
https://www.ncbi.nlm.nih.gov/pubmed/35326648
http://dx.doi.org/10.3390/cancers14061498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946798/
https://www.ncbi.nlm.nih.gov/pubmed/35326648
http://dx.doi.org/10.3390/cancers14061498

Ejemplares similares